New and generic drug assessment goals are not expected to be adjusted because of coronavirus-mandated telework, but senior US Food and Drug Administration officials indicated other aspects of the clearance process could affect output.
During a 27 March interview with the Pink Sheet via teleconference, Office of New Drugs Director Peter Stein and Office...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?